Allen Borchardt

This inventor holds 19 USPTO granted patents and 12 published patent applications and 2 EPO patents. Top assignees: Agouron Pharmaceuticals, Inc., Cidara Therapeutics, Inc., Kalypsys, Inc.. Active years: 2003-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Allen Borchardt. Retrieved from https://idiyas.com/inventor/allen-borchardt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 12)

% Patents Active = 57.9

EPO Patents = 2 (Patent Applications = 12)

Average Co-Inventor Count = 6.3

ph-index = 8

Forward Citations = 531(Granted Patents)

Company Filing History:

10 out of 174

Agouron Pharmaceuticals, Inc.

patents

4 out of 16

Cidara Therapeutics, Inc.

Lawrence Livermore National Security, LLC

patents

5. 2 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2003-2026

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12569565 - COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS (2026-03-10),

2. 12427200 - Compositions and methods for the treatment of viral infections (2025-09-30),

3. 11833213 - Compositions and methods for the treatment of viral infections (2023-12-05),

4. 11510992 - Compositions and methods for the treatment of viral infections (2022-11-29),

5. 10865216 - Tricyclic Gyrase inhibitors (2020-12-15),

6. 10385055 - Tricyclic gyrase inhibitors (2019-08-20),

7. 8569300 - Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease (2013-10-29),

8. 8080566 - Carbazole inhibitors of histamine receptors for the treatment of disease (2011-12-20),

9. 7473790 - Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same (2009-01-06),

10. 7148226 - Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same (2006-12-12),

11. 7141587 - Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use (2006-11-28),

12. 7115658 - Inhibitors of hepatitis C virus RNA-dependent RNA polymerase (2006-10-03),

13. 7053107 - Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use (2006-05-30),

14. 6891044 - Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use (2005-05-10),

15. 6884890 - Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use (2005-04-26),

Title: **Allen Borchardt: A Pioneer in Viral Infection Treatment Innovations**

Introduction

Allen Borchardt is a prominent inventor based in San Diego, California, with a remarkable portfolio of 17 patents. His innovative work primarily focuses on the treatment of viral infections, making significant strides in the medical field. This article will explore his latest patents, career highlights, and collaborations that showcase his contributions to science and technology.

Latest Patents

Borchardt's latest patents revolve around compositions and methods for the treatment of viral infections. These inventions include conjugates containing inhibitors of viral neuraminidase, such as zanamivir and peramivir, which are linked to an Fc monomer, Fc domain, or Fc-binding peptide, as well as albumin proteins or albumin-binding peptides. These conjugates hold promise for treating viral infections, particularly influenza.

Career Highlights

Throughout his career, Allen Borchardt has worked with esteemed companies such as Agouron Pharmaceuticals, Inc. and Kalypsys, Inc. His work has been instrumental in developing novel therapeutic strategies, and his 17 patents reflect his commitment to advancing medical science.

Collaborations

Borchardt has collaborated with influential scientists in the field, including Robert Steven Kania and Steven Lee Bender. These partnerships have contributed to his successful research and the development of innovative solutions for viral infections.

Conclusion

Allen Borchardt's contributions as an inventor have made significant impacts on the treatment of viral infections. His dedication to innovation and collaboration with peers highlight the importance of teamwork in scientific discovery. As he continues to push the boundaries of medical research, his work will undoubtedly inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.